Tomoki Yamatsuji

Tomoki Yamatsuji

Auto-generated profile, based on publicly available information

Tomoki Yamatsuji

Department of General Surgery, Kawasaki Medical School, Okayama, Japan

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
KTkoichi tomoshige
koichi tomoshige
WSWilliam D. Stuart
William D. Stuart
IFIris M. Fink-Baldauf
Iris M. Fink-Baldauf
MIMasaoki Ito
Masaoki Ito
Tomoshi TsuchiyaTomoshi Tsuchiya
Tomoshi Tsuchiya
YMYutaka Maeda
Yutaka Maeda
The endoderm-lineage transcription factor FOXA2 has been shown to inhibit lung tumorigenesis in in vitro and xenograft studies using lung cancer cell lines. However, FOXA2 expression in primary lung tumors does not correlate with an improved patient survival rate, and the functional role of FOXA2 in primary lung tumors remains elusive. To understand the role of FOXA2 in primary lung tumors in vivo, here, we conditionally induced the expression of FOXA2 along with either of the two major lung cancer oncogenes, EGFRL858R or KRASG12D, in the lung epithelium of transgenic mice. Notably, FOXA2 suppressed autochthonous lung tumor development driven by EGFRL858R, whereas FOXA2 promoted tumor growth driven by KRASG12D. Importantly, FOXA2 expression along with KRASG12D produced invasive mucinous adenocarcinoma (IMA) of the lung, a fatal mucus-producing lung cancer comprising approximately 5% of human lung cancer cases. In the mouse model in vivo and human lung cancer cells in vitro, FOXA2 activated a gene regulatory network involved in the key mucous transcription factor SPDEF and upregulated MUC5AC, whose expression is critical for inducing IMA. Coexpression of FOXA2 with mutant KRAS synergistically induced MUC5AC expression compared with that induced by FOXA2 alone. ChIP-seq combined with CRISPR interference indicated that FOXA2 bound directly to the enhancer region of MUC5AC and induced the H3K27ac enhancer mark. Furthermore, FOXA2 was found to be highly expressed in primary tumors of human IMA. Collectively, this study reveals that FOXA2 is not only a biomarker but also a driver for IMA in the presence of a KRAS mutation. Significance: FOXA2 expression combined with mutant KRAS drives invasive mucinous adenocarcinoma of the lung by synergistically promoting a mucous transcriptional program, suggesting strategies for targeting this lung cancer type that lacks effective therapies.

16 March 2024 in Cancer Letters
Verified
Journal Article
Open access
EYEtsuko Yokota
Etsuko Yokota
MIMiki Iwai
Miki Iwai
TYTakuro Yukawa
Takuro Yukawa
YNYoshio Naomoto
Yoshio Naomoto
MHMinoru Haisa
Minoru Haisa
TYTomoki Yamatsuji
Tomoki Yamatsuji
Pulmonary large-cell neuroendocrine carcinoma (LCNEC), a disease with poor prognosis, is classified as pulmonary high-grade neuroendocrine carcinoma, along with small-cell lung cancer. However, given its infrequent occurrence, only a limited number of preclinical models have been established. Here, we established three LCNEC tumoroids for long-term culture. Whole-exome sequencing revealed that these tumoroids inherited genetic mutations from their parental tumors; two were classified as small-cell carcinoma (S-LCNEC) and one as non-small cell carcinoma (N-LCNEC). Xenografts from these tumoroids in immunodeficient mice mimicked the pathology of the parent LCNEC, and one reproduced the mixed-tissue types of combined LCNEC with a component of adenocarcinoma. Drug sensitivity tests using these LCNEC tumoroids enabled the evaluation of therapeutic agent efficacy. Based on translational research, we found that a CDK4/6 inhibitor might be effective for N-LCNEC and that Aurora A kinase inhibitors might be suitable for S-LCNEC or LCNEC with MYC amplification. These results highlight the value of preclinical tumoroid models in understanding the pathogenesis of rare cancers and developing treatments. LCNEC showed a high success rate in tumoroid establishment, indicating its potential application in personalized medicine.

1 January 1998 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
MMMasayuki Matsushita
Masayuki Matsushita
RORyoko Ono
Ryoko Ono
JMJunji Matsuoka
Junji Matsuoka
TYTomoki Yamatsuji
Tomoki Yamatsuji
YNYoshio Naomoto
Yoshio Naomoto
HMHideki Matsui
Hideki Matsui
Cell motility is involved in physiological and pathological processes such as the invasion and migration of cells. c-Jun N-terminal kinase (JNK) cascades are involved in the invasion and metastasis of cancer cells. However, little is known about the downstream signaling of JNK. In the present study, we used small interfering RNA (siRNA) directed against JNK1 to reduce its expression. We used microarray techniques to compare the gene expression profiles of epidermal growth factor (EGF)-stimulated HeLa cells with and without JNK1 siRNA treatment. We identified a JNK1 target gene, myosin phosphatase-Rho interacting protein (M-RIP). RNA interference-mediated inhibition of JNK1 strongly inhibited M-RIP mRNA expression induced by EGF, as well as the invasion of HeLa cells. In addition, M-RIP siRNA-treated cells showed significantly reduced invasive activity. Thus, a functional analysis of JNK1 and M-RIP with RNA interference reveals a critical role for this cascade in the invasive behavior of cancer cells.

4 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
TATakatoshi Anno
Takatoshi Anno
TYTomoki Yamatsuji
Tomoki Yamatsuji
KTKoichi Tomoda
Koichi Tomoda
SNShuhei Nakanishi
Shuhei Nakanishi
HKHideaki Kaneto
Hideaki Kaneto
Capecitabine has been used for the treatment of various types of tumors. The rare side effects induced by capecitabine have been reported as hypertriglyceridemia, acute pancreatitis associated with hypertriglyceridemia and hypertriglyceridemia complicated with hyperglycemia. The mechanisms of capecitabine-induced hypertriglyceridemia are unclear. In this report, we present a subject with sigmoid colon cancer and capecitabine-induced dyslipidemia. LDL-cholesterol level was markedly elevated throughout the long period of treatment with capecitabine. In addition, triglyceride level was high and not stable during the treatment period. Her dyslipidemia was ameliorated by the treatment with 5 mg of rosuvastatin, which is one of the HMG-CoA reductase inhibitors.

23 November 2022 in Surgery Today
Verified
Journal Article
Closed access
PDF file
ESENDO SHUNJI
ENDO SHUNJI
TYTomoki Yamatsuji
Tomoki Yamatsuji
YFYoshinori Fujiwara
Yoshinori Fujiwara
MHMasaharu Higashida
Masaharu Higashida
HKHisako Kubota
Hisako Kubota
TUTomio Ueno
Tomio Ueno

1 January 2018 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
NONobuaki Ochi
Nobuaki Ochi
TWTokio Wakabayashi
Tokio Wakabayashi
AUAtsushi Urakami
Atsushi Urakami
TYTomoki Yamatsuji
Tomoki Yamatsuji
NINaoto Ikemoto
Naoto Ikemoto
Nagio TakigawaNagio Takigawa
Nagio Takigawa
A 26-year-old man with right lower mandibular and chest pain, fever, and respiratory distress was urgently transported to our hospital. CT images revealed gas collection and an abscess from the neck to the mediastinum with bilateral pleural effusion. Descending necrotizing mediastinitis (DNM) induced by an odontogenic infection of a right mandibular molar abscess was diagnosed. The cervical and mediastinal areas were drained, extensive debridement was performed, necrotic tissue was excised, and broad-spectrum antibiotics were administered immediately. Prompt diagnosis and intensive care were necessary for managing the DNM, and the patient was discharged with no comorbidities.